Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
32°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
826.71
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Dec 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
MarketBeat Week in Review – 12/2 - 12/6
December 07, 2024
Equities continued their post-election rally after Friday’s solid November jobs report and all signs point to the rally in stocks extending into 2025
Via
MarketBeat
Topics
Economy
Government
Immigration
Exposures
Economy
Immigration
Interest Rates
3 No-Brainer Growth Stocks to Buy in December
December 07, 2024
Via
The Motley Fool
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
December 07, 2024
Via
The Motley Fool
Eli Lilly Stock Price Analysis – Earnings Miss And The Pullback Worth Watching
December 06, 2024
The company lowered its FY2024 guidance following Q3 earnings, citing supply chain challenges for top-selling drugs like Mounjaro and Zepbound and a one-time R&D expense from its $3.2 billion...
Via
Talk Markets
Topics
Earnings
Economy
Stocks / Equities
Exposures
Financial
Supply Chain
Eli Lilly Investments In Production Reach $23 Billion With Additional $3 Billion Expansion At US Facility
December 06, 2024
Eli Lilly plans a $3 billion expansion of its Wisconsin facility, creating 750 skilled jobs and boosting production capacity for critical medicines with advanced automation.
Via
Benzinga
Are you living with eczema? It's time to get the care you deserve
December 05, 2024
(BPT) - Sponsored by Eli Lilly and Company
Via
Brandpoint
Decoding Eli Lilly's Options Activity: What's the Big Picture?
December 04, 2024
Via
Benzinga
Alzheimer’s Disease Therapy Provides Patients With Hope
December 06, 2024
(BPT) - (In Partnership with Eli Lilly and Company)
Via
Brandpoint
Stock Market Hits Highs On Salesforce, Tech Earnings; Bitcoin Tops $100,000, Briefly: Weekly Review
December 06, 2024
Salesforce and mostly positive tech earnings buoyed the major indexes.
Via
Investor's Business Daily
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
December 06, 2024
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies.
Via
MarketBeat
Billionaire Izzy Englander Is Buying This Obesity Drug Stock That Could Soar Nearly 20%, According to Wall Street
December 06, 2024
Via
The Motley Fool
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
December 05, 2024
GoodRx's latest research shows surging demand for weight loss medications like Wegovy and Zepbound, despite high costs and limited insurance coverage, with consumers overspending $200 million in 2024.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
December 05, 2024
Via
Benzinga
2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick
December 05, 2024
Discover two telehealth stocks, Hims & Hers (HIMS) and Teladoc (TDOC), poised to benefit from Trump's FDA nominee, Dr. Marty Makary, a telemedicine advocate.
Via
MarketBeat
Topics
Government
Lawsuit
Exposures
Financial
Legal
Political
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market
December 05, 2024
An age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in obesity.
Via
Investor's Business Daily
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
December 05, 2024
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable.
Via
The Motley Fool
Lilly Tops Nordisk In Weight Loss Battle
December 05, 2024
The two market-leading weight loss/obesity drugs (GLP-1), Zepabound (Eli Lilly) and Wegovy (Novo Nordisk), just completed a clinical side-by-side trial.
Via
Talk Markets
Topics
Stocks / Equities
10 Health Care Stocks Whale Activity In Today's Session
December 04, 2024
Via
Benzinga
Stock Of The Day: Where Will The Eli Lilly Rally End?
December 04, 2024
Shares of Eli Lilly (LLY) are approaching a price level that had previously been a peak. There is a good chance they hit resistance at it.
Via
Benzinga
Eli Lilly Stock Hits 3-Week High, Boosts Retail Mood On Zepbound’s Edge Over Wegovy In Weight-Loss Trial Showdown
December 04, 2024
Participants lost an average of 20.2% body weight on Zepbound versus 13.7% on Wegovy over 72 weeks.
Via
Stocktwits
Eli Lilly's Zepbound Vs. Novo Nordisk's Wegovy - Which Shows Greater Weight Loss?
December 04, 2024
Eli Lilly's Zepbound outperformed Wegovy in weight loss and key outcomes during the SURMOUNT-5 trial, showing a comparable safety profile.
Via
Benzinga
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
December 04, 2024
Navitas Semiconductor is losing money according to Jim Cramer. LandBridge Company is a winner, while Regeneron is facing sales challenges.
Via
Benzinga
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy In Head-To-Head Weight-Loss Trial
December 04, 2024
Lilly touted findings from the first head-to-head clinical trial.
Via
Investor's Business Daily
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
December 04, 2024
Via
The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
December 03, 2024
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market.
Via
Benzinga
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
December 03, 2024
Defiance ETFs introduces NVOX, a leveraged ETF offering 2X exposure to Novo Nordisk's stock price movements, targeting the booming weight loss market with tactical trading opportunities.
Via
Benzinga
Topics
ETFs
Eli Lilly Gap
December 02, 2024
I took on a bearish position on Eli Lilly (LLY) today. I think the days of Big Pharma just printing up profits out of thin air are over.
Via
Talk Markets
Topics
Stocks / Equities
It’s Been A Tough Month For Healthcare Stocks
December 02, 2024
It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Macy's Multimillion-Dollar Error
December 02, 2024
We also talk about snack foods, AI, Netflix's strategy on live events, and more.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
December 02, 2024
Pharma companies lobby for changes to Medicare drug price rules, targeting a four-year delay for pills' eligibility. Critics warn it may hinder patient access and innovation.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.